Nov 27 (Reuters) - Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.

The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in SLE patients.

SLE is a chronic autoimmune disease that causes inflammation as the immune system that normally helps protect the body from infection and diseases attacks its own tissues.

Roivant said it did not intend to progress the program in SLE, but will continue to advance the drug in other ongoing trials.

(Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri and Shinjini Ganguli)